Otic administration of amphotericin B 0.25% in sterile water.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Otic administration of amphotericin B 0.25% in sterile water.

Ann Pharmacother. 1994 Mar;28(3):333-5. Unique Identifier : AIDSLINE MED/94250989
Kintzel PE; Trausch DE; Copfer AL; Inpatient Pharmacy, University Medical Center, University of; Arizona Health Sciences Center, Tucson 85724.

Abstract: OBJECTIVE: To report otic administration of parenteral amphotericin B 0.25% in sterile water. CASE SUMMARY: A 44-year-old HIV+ man was diagnosed with otitis externa. The patient's past medical history was remarkable for positive Coccidioides immitis serology for more than five months, essential hypertension, and Barrett's esophagitis. Culture results from an ear swab revealed 4+ Aspergillus fumigatus and 3+ Staphylococcus, coagulase negative. Antiinfective therapy for the otitis externa included oral and topical antibacterial and antifungal medications. Amphotericin B 0.25% in sterile water was prepared by the pharmacy for topical otic administration. The otic amphotericin B was dispensed with instructions to refrigerate and assigned a one-week expiration date. The prescription called for instillation of 1-2 drops in each ear three times a day. The patient's signs and symptoms of otitis externa resolved during several weeks of antiinfective therapy. Topical administration of amphotericin B 0.25% in sterile water was not associated with any local adverse effects in this patient. DISCUSSION: The rationale for use of the parenteral amphotericin B formulation to prepare an otic dosage form, and the rationale for the specific concentration and expiration date chosen are discussed. CONCLUSIONS: This patient tolerated topical otic administration of amphotericin B 0.25% in sterile water when administered three times daily.

Keywords: Administration, Topical Adult Amphotericin B/*ADMINISTRATION & DOSAGE/THERAPEUTIC USE Aspergillosis/*DRUG THERAPY *Aspergillus fumigatus Case Report Drug Administration Routes Drug Administration Schedule Ear Canal Human HIV Seropositivity Male Otitis Externa/*DRUG THERAPY Water JOURNAL ARTICLE

940930
M9491023

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .